Medical Articles

Dabigatran

Direct thrombin inhibitor (DTI - Novel Oral Anticoagulant - NOAC)

Description

Oral direct thrombin (factor IIa) inhibitor for stroke prevention in AF and VTE treatment. RE-LY trial showed superiority to warfarin in stroke prevention and significantly lower intracranial hemorrhage.

Mechanism of action

Selectively and reversibly inhibits thrombin (factor IIa), preventing fibrin clot formation and thrombin-mediated platelet aggregation. Rapid onset and reversible binding provide predictable pharmacokinetics.

This page is restricted. Please Login / Register to view this page.

Mechanism of action

Selectively and reversibly inhibits thrombin (factor IIa), preventing fibrin clot formation and thrombin-mediated platelet aggregation. Rapid onset and reversible binding provide predictable pharmacokinetics.

This page is restricted. Please Login / Register to view this page.